Targets › P2RX3
2 programs from 2 companies in 3 trials: 2 Phase 3, 1 Phase 2; Respiratory, Gastroenterology, Other; next expected readout Mar 2027.
Extracellular ATP-activated non-selective cation channel. Plays particularly important role in sensory neurons where its activation is critical for gustatory, nociceptive responses, visceral reflexes and sensory hypersensitization (By similarity). (UniProt, P56373)
Open in Phaseline: the race on P2RX3, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| GSK | Camlipixant (BLU-5937) P2X purinoceptor 3 antagonist | P2RX3 | Phase 3 | Refractory Chronic Cough; Irritable Bowel Syndrome | Mar 2027 |
| Bellus Health Inc. - a GSK company | Camlipixant (BLU-5937) P2X purinoceptor 3 antagonist | P2RX3 | Phase 3 | Cough | Mar 2027 |
Cough (1) Refractory Chronic Cough (1) Irritable Bowel Syndrome (1)
small molecule (2)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.